3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
76
Squamous Cell Carcinoma of Head and Neck
43
Lung Neoplasms
34
Oropharyngeal Neoplasms
22
Urinary Bladder Neoplasms
20
Head and Neck Neoplasms
18
Nasopharyngeal Carcinoma
17
Carcinoma
15
Biliary Tract Neoplasms
15
Small Cell Lung Carcinoma
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Neoplasm Metastasis
13
Esophageal Squamous Cell Carcinoma
13
Cholangiocarcinoma
13
Colorectal Neoplasms
12
Uterine Cervical Neoplasms
11
Pancreatic Neoplasms
11
Neoplasms
11
Carcinoma, Squamous Cell
11
Ovarian Neoplasms
10
Mouth Neoplasms
9
Laryngeal Neoplasms
9
Gallbladder Neoplasms
8
Endometrial Neoplasms
8
Carcinoma, Transitional Cell
8
Hypopharyngeal Neoplasms
7
Esophageal Neoplasms
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Mesothelioma, Malignant
6
Interventions
Specimen Handling
6
pembrolizumab
4
enfortumab vedotin
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
3
cabozantinib
2
Nivolumab
2
Carboplatin
2
Biopsy
2
relatlimab
1
eribulin
1
erdafitinib
1
avelumab
1
atezolizumab
1
Watchful Waiting
1
Standard of Care
1
Practice Guidelines as Topic
1
Plasmapheresis
1
Plasma Exchange
1
Observation
1
Lenalidomide
1
Ipilimumab
1
Doxorubicin
1
Cystoscopy
1
Contrast Media
1
Cisplatin
1
Central Venous Catheters
1
CTLA-4 Antigen
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
Cisplatin
×
90 days
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA